APPILI THERAPEUTICS INC - APLIF STOCK NEWS

Aditxt (NASDAQ: ADTX) announced a significant milestone in its acquisition plans for Appili Therapeutics (TSX: APLI; OTCPink: APLIF). At a special meeting, Appili's shareholders voted overwhelmingly in favor of a plan of arrangement that would allow Aditxt to acquire all issued and outstanding Class A common shares of Appili. This development marks a important step forward in Aditxt's strategy to expand its healthcare innovation platform.

Aditxt (NASDAQ: ADTX) has announced a significant development regarding its target acquisition, Appili Therapeutics (TSX: APLI; OTCPink: APLIF). The U.S. Food and Drug Administration (FDA) has provided positive feedback on the development strategy for ATI-1801, Appili's topical antiparasitic product. This feedback aligns with the requirements for the New Drug Application (NDA) submission.

Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) announced an update on their biodefense program ATI-1701 at IDWeek 2024™. The presentation, scheduled for October 17, 2024, will showcase new data on the efficacy of ATI-1701, a potential first-in-class vaccine candidate for tularemia prevention. Preclinical studies have demonstrated that a single dose of ATI-1701 provides full protection against lethal tularemia in animal models one year after vaccination.

Appili has secured a US$14 million funding commitment from the United States Air Force Academy, in partnership with the Defense Threat Reduction Agency. This funding is expected to advance the ATI-1701 program towards an IND submission to the FDA in 2025. The company's management will be available for meetings throughout the conference.

Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) has issued a correction to its October 10, 2024 press release regarding the proposed arrangement with Aditxt, Inc. The initial press release incorrectly stated the cash consideration for each Appili share as US$ 0.467. The correct cash amount is US$ 0.0467 per Appili Share.

Under the corrected terms of the arrangement, for each Class A common share of Appili, shareholders will receive:

• US$ 0.0467 in cash
• 0.0000686251 of a share of Aditxt common stock (valued at approximately US$0.00013 per Appili Share based on Aditxt's closing price on October 3, 2024)

This correction is significant as it substantially reduces the cash component of the consideration for Appili shareholders in the proposed arrangement with Aditxt, Inc.

Aditxt (NASDAQ: ADTX) announced that Appili Therapeutics (TSX: APLI; OTCPink: APLIF) will hold a special meeting on November 6, 2024, for shareholders to vote on Aditxt's proposed acquisition. Appili's board recommends voting in favor. Appili has raised CAD $100M for developing infectious disease and biodefense therapeutics. Its portfolio includes:

1. LIKMEZ™: FDA-approved liquid antibiotic

2. ATI-1701: Tularemia vaccine with $14M in funding

3. ATI-1801: Topical treatment for cutaneous leishmaniasis

Two programs may be eligible for FDA Priority Review Vouchers. The acquisition aims to expand Aditxt's reach in addressing infectious diseases and public health challenges.

Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) announces its special meeting of shareholders on November 6, 2024, to vote on the acquisition by Aditxt Inc. through its subsidiary Adivir, Inc. The arrangement offers shareholders US$0.467 in cash and 0.000686251 Aditxt shares per Appili share. Appili's board recommends voting in favor of the resolution. The deal aims to accelerate Appili's programs, enhance access to capital, and leverage Aditxt's expertise in development and commercialization.

Key highlights include:

• Advancing LIKMEZ™, an FDA-approved liquid oral reformulation of metronidazole
• Accelerating ATI-1701 development towards IND submission in 2025
• Advancing clinical development of ATI-1801 for cutaneous leishmaniasis
• Exploring additional infectious disease development opportunities

Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF), a biopharmaceutical company focused on infectious diseases and medical countermeasures, held its annual and special meeting of shareholders on September 17, 2024. All tabled resolutions were approved, including the election of six directors: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni, and Prakash Gowd. The shareholders also approved the re-appointment of PricewaterhouseCoopers, LLP as the independent auditor, and passed special resolutions for the Company's continuation from the Canada Business Corporations Act to the Ontario Business Corporations Act (OBCA). Additionally, shareholders authorized the board to set the number of directors within the limits set in the Company's articles, in accordance with the OBCA.

Aditxt Inc. (NASDAQ: ADTX) has announced a third amendment to its arrangement agreement with Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF). Key changes include:

1. Extending the Outside Date to November 19, 2024
2. Requiring Appili to convene a shareholder meeting promptly
3. Changing the deadline for Aditxt's financing completion to October 18, 2024
4. Making the Continuance a condition for completing the arrangement

The transaction remains subject to Aditxt raising at least $20 million in financing and other customary conditions. Upon completion of the Appili and Evofem Biosciences transactions, Aditxt plans to introduce two new programs focused on public health and women's health, expanding its current immune health and precision health programs.

Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) reported its Q1 FY2025 financial results, ending June 30, 2024. Key highlights include:

1. A definitive agreement with Aditxt, offering a premium to shareholders if approved.

2. ATI-1701 secured $14 million in USAFA funding commitments.

3. FDA engagement for ATI-1801's registration strategy.

4. LIKMEZ™ (ATI-1501) launched in the US market.

5. Net loss of $1.6 million ($0.01 per share), slightly higher than Q1 FY2024.

6. Cash position of $0.3 million as of June 30, 2024.

The company is advancing its infectious disease programs, focusing on ATI-1701, ATI-1801, and LIKMEZ™, aiming to benefit patients and shareholders.